News for Genmab A/S (GMABN.MX)

Published at

Jul 26, 2025 4:37 AM

by finance.yahoo.com

mixed

mixed

Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Genmab A/S stands eighth on our list and has recently opened new sites in the US. Genmab A/S (NASDAQ:GMAB), a Danish biotech company founded in 1999, specializes in antibody-based therapies for cancer and serious diseases. Known for its technologies like HuMab-Mouse […]

JNJ DJNJ3.BA DJNJ2.BA GNMSF GMABN.MX GMAB

Read more →
Published at

Jul 23, 2025 11:35 AM

by manilatimes.net

positive

positive

European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma

Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring1

JNJ GNMSF GMABN.MX GMAB DJNJ3.BA DJNJ2.BA

Read more →
Published at

Jul 22, 2025 8:03 AM

by manilatimes.net

positive

positive

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety

SCNLF SCLP.L GNMSF GMABN.MX GMAB

Read more →
Published at

Jul 16, 2025 2:55 PM

by gurufocus.com

positive

positive

Genmab (GMAB) Reports Strong Darzalex Sales in Q2 2025

Key Takeaways: Darzalex's impressive Q2 2025 net sales boost Genmab's revenue stream through royalty agreements with J&J. Genmab's stock presents substan

JNJ GNMSF GMABN.MX GMAB DJNJ3.BA DJNJ2.BA

Read more →
Published at

Jul 10, 2025 5:14 PM

by finance.yahoo.com

mixed

mixed

UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT

Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 25, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) and set a price target of DKK2,500.00. The company reported $715 million in revenue for the first three months of 2025 compared to $603 million […]

JNJ DJNJ3.BA DJNJ2.BA GNMSF GMABN.MX GMAB

Read more →
Published at

Jul 1, 2025 2:29 PM

by manilatimes.net

mixed

mixed

Genmab Announces Changes to its Executive Committee

Media Release

GNMSF GMABN.MX GMAB AZN

Read more →
Published at

Jun 30, 2025 3:37 PM

by manilatimes.net

neutral

neutral

Completion of Share Buy-back Program

Company Announcement

GNMSF GMABN.MX GMAB

Read more →
Published at

Jun 23, 2025 3:18 PM

by seekingalpha.com

neutral

neutral

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One (NASDAQ:GMAB)

Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and undervalued metrics. Click for more on GMAB.

GNMSF GMABN.MX GMAB

Read more →
Published at

Jun 20, 2025 12:50 PM

by manilatimes.net

positive

positive

DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma

**media[660116]**

JNJ GNMSF GMABN.MX GMAB DJNJ3.BA DJNJ2.BA

Read more →
Published at

Jun 17, 2025 7:48 PM

by manilatimes.net

positive

positive

Capital Increase in Genmab as a Result of Employee Warrant Exercise

**media[657686]**

GNMSF GMABN.MX GMAB

Read more →
Published at

Jun 16, 2025 3:34 PM

by manilatimes.net

neutral

neutral

Transactions in Connection with Share Buy-back Program

**media[656112]**

GNMSF GMABN.MX GMAB

Read more →
Published at

Jun 15, 2025 12:15 PM

by gurufocus.com

positive

positive

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autol

Epcoritamab combination therapy shows promising results in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients. Study demonstrates 87%

GNMSF GMABN.MX GMAB

Read more →
Published at

Jun 12, 2025 7:21 PM

by manilatimes.net

neutral

neutral

Grant of Restricted Stock Units and Warrants to Employees in Genmab

**media[653452]**

GNMSF GMABN.MX GMAB

Read more →
Published at

Jun 10, 2025 1:45 PM

by manilatimes.net

neutral

neutral

Transactions in Connection with Share Buy-back Program

**media[650522]**

GNMSF GMABN.MX GMAB

Read more →
Published at

Jun 3, 2025 6:50 AM

by insidermonkey.com

negative

negative

Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer

Results from the Phase 1/2 RAINFOL-01 trial, presented at the 2025 ASCO Annual Meeting, show that Rina-S 100 mg/m² administered every three weeks achieved a confirmed objective response rate (ORR) of...

GNMSF GMABN.MX GMAB

Read more →
Published at

Jun 2, 2025 9:45 PM

by gurufocus.com

negative

negative

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Tr

Rinatabart sesutecan (Rina-S®) showed a 50% objective response rate in advanced endometrial cancer patients during the Phase 1/2 RAINFOLâ„¢-01 trial. T

GNMSF GMABN.MX GMAB

Read more →
Published at

May 27, 2025 4:09 PM

by manilatimes.net

neutral

neutral

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

**media[638247]**

GNMSF GMABN.MX GMAB

Read more →
Published at

May 26, 2025 2:39 PM

by manilatimes.net

neutral

neutral

Transactions in Connection with Share Buy-back Program

**media[637000]**

GNMSF GMABN.MX GMAB

Read more →
Published at

May 23, 2025 7:49 AM

by insidermonkey.com

positive

positive

Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025

Genmab A/S (NASDAQ:GMAB) announced that it will present pivotal new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30...

GNMSF GMABN.MX GMAB

Read more →
Published at

May 23, 2025 7:49 AM

by finance.yahoo.com

neutral

neutral

Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025

Genmab A/S (NASDAQ:GMAB) announced that it will present pivotal new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 to June 3 in Chicago. Key highlights include the first public results from a Phase 1/2 trial of rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate […]

GNMSF GMABN.MX GMAB

Read more →